A c c e p t e d M a n u s c r i p t the cells and other constituents of the tumour microenvironment play a key role in disease outcome (1) . Fibroblasts are one of the most numerous cells in the tumour microenvironment and act to modulate both cancer cell behaviour and the host immune responses by remodelling the extracellular matrix (ECM) and secreting a wealth of soluble factors able to interact with nearby cellular receptors via cell autonomous and subservient mechanisms (2) . The phenotypes of the fibroblasts surrounding a tumour (collectively termed cancer associated fibroblasts; CAF) are complex and varied, but certain CAF features are strongly associated with cancer cell dissemination and poor outcome (3) . The best characterized of these is the presence of 'myofibroblastic' CAF; cells expressing alpha smooth muscle actin (αSMA) which at least superficially resemble myofibroblasts found transiently in healing wounds (4) . Myofibroblastic CAF are contractile, secretory cells that generate an altered extracellular matrix and are generally accepted to contribute to an extracellular milieu supportive of cancer cell invasion and metastasis (2) . The presence of αSMA-rich CAF is correlated with poor outcome in a number of cancers, suggesting a key role in disease progression (3, (5) (6) (7) . The source of myofibroblastic CAF is controversial but at least some are likely to arise from differentiation (or 'activation') of resting fibroblasts provoked by signals, such as TGF-β1, released from cancer cells and inflammatory cells recruited to the tumour microenvironment (8) .
Despite the wealth of data supporting a role for CAF in contributing to tumour metastasis, little is known of the mechanisms underlying CAF development from resident stromal fibroblasts. Here, we applied an in silico approach to identify a microRNA, miR-145, found predominantly in mesenchymal cells (9) , putatively able to target components of the TGF-β1 signalling pathway. We subsequently examined 
Materials and methods
Routine tissue culture: All cells were routinely cultured in Dulbecco's modification of Eagle's medium (DMEM), supplemented with 10% (v/v) foetal bovine serum (FBS) and 2 mM L-glutamine, without antibiotics at 37 °C with 5% (v/v) CO 2 . Primary fibroblasts were used within 3-9 passages. For TGF-β1 treatment, oral fibroblasts were seeded at 250,000 cells per well in a six well plate, allowed to settle before being serum starved for 24 h before treatment with 5 ng/ml TGF-β1 for 24-96 h (as indicated in individual figure legends) in serum free DMEM supplemented with 2 mM L-glutamine. A c c e p t e d M a n u s c r i p t and CAF10 were obtained from GU-SCC (genetically unstable-SCC) biopsies known to contain tumourigenic SCC keratinocytes whereas GS-SCC CAF (genetically stable-SCC), CAF1, CAF3, CAF5, CAF6 & CAF7 were obtained from GS-SCC biopsies (11) (12) (13) , In addition to NOF cultures, normal human oral fibroblast cultures NHOF-1 and NHOF-5 were obtained from the University of Peridanya, Kandy, Sri Lanka (14) . Human primary dermal fibroblasts, HDF1 (Promocell) and HDF2 (09/H1308/66) were kind gifts from Dr Simon Whawell and Prof Sheila MacNeil respectively. H357, a cell line isolated from tongue OSCC (15) , was obtained from ATTCC and cell identity was confirmed by satellite tandem repeat (STR) analysis of cells within 10 passages.
The primary fibroblasts used in this study were isolated from separate institutions using adapted protocols. A full table of the cells used in this study and the isolation methods are given in table 1.
Fibroblast isolation: Primary fibroblasts were isolated from oral biopsies as previously described (Hearnden et al., 2009) , where the keratinocytes were removed by incubation with 0.1% (w/v) Difco trypsin (BD Biosciences) at 4°C overnight and subsequently scraped with a scalpel to collect the epithelium. The remaining tissue was finely minced and enzymatically digested with collagenase (0.5% (v/v)) at 37°C with 5 % (v/v) CO 2 overnight. The collagenase suspension was centrifuged at 2000 rpm for 10 min to retrieve the NOFs. NOFs were initially cultured with routine culture media containing 0.625 µg/ml amphotericin B and 100 i.u./ml penicillin and 100 µg/ml streptomycin, before removing the antibiotics for experimental use. Contractility assay: Fibroblast-populated collagen gels were prepared as previously described (16) A c c e p t e d M a n u s c r i p t assess significance in differential gene expression in NOFs and CAF. All data presented is n=3, unless otherwise stated. N=3 refers to biological replicates from the same fibroblast strain, however each experiment has been repeated in at least 2 strains and a representative figure was selected and shown for conciseness.
Results

TGF-β1 stimulates pro-tumourigenic myofibroblast transdifferentiation
The ability of TGF-β1 to induce myofibroblast transdifferentiation of primary human fibroblasts was examined using several established markers of the myofibroblast phenotype (19) (20) (21) (22) (23) . Treatment of oral fibroblasts with TGF-β1 (5 ng/ml) resulted in a time-dependent increase in the expression of αSMA, versican (VCAN, V0 isoform) and fibronectin 1 extra domain A (FN1-EDA) transcripts (Fig 1a-c) , with a corresponding increase in αSMA protein levels and the appearance of αSMA-rich stress fibres (Fig 1d&e) . This was associated with increased ability to contract collagen I lattices (Fig 1f) , in keeping with previous reports (22) . Conditioned medium from TGF-β-induced myofibroblasts promoted more cancer cell migration and invasion than medium from untreated fibroblasts (Fig 1g&h) . It is noteworthy that not all the different cultures of primary fibroblasts tested, obtained from different patients, responded equally to TGF-β1 ( Fig S1) .
MicroRNA-145 is upregulated during myofibroblast transdifferentiation
In order to begin to examine the molecular mechanisms underlying the TGF-βinduced acquisition of a pro-tumourigenic, myofibroblastic phenotype by primary fibroblasts, we carried out an in silico analysis to identify miRNA predicted to target components of the TGF-β1 signalling pathway, using a variety of online algorithms M a n u s c r i p t including DIANA (http://diana.cslab.ece.ntua.gr/). One of the candidate miRNA identified using this approach, miR-145, is predicted or functionally demonstrated in the literature to have numerous targets or putative targets in the TGF-β1 pathway (Fig 2a) , and was upregulated in response to TGF-β1 treatment in a number of NOF and CAF (isolated from patients with oral squamous cell carcinomas (14)) cultures analysed (Fig 2b&c) but with heterogeneity in response between different cultures.
Having identified a putative role for miR-145 in fibroblast responses to TGF-β1, we next analysed the expression levels of mature miR-145 in a panel of ten NOF and ten CAF miR-145 expression was statistically significantly higher in CAF than in normal oral fibroblasts (Fig 2d) .
miR-145 inhibits myofibroblast differentiation in response to TGF-β1
In order to examine the effect of miR-145 on myofibroblast differentiation, a synthetic miRNA functionally mimicking mature miR-145 or a control, non-targeting miRNA, were transfected into primary oral fibroblasts and the effect on markers of the myofibroblastic phenotype was examined. Over-expression of miR-145 (Fig 3a) resulted in an almost complete abolition of the ability of TGF-β1 to induce αSMA transcript levels (Fig 3b) and a reduction of TGF-β-induced αSMA protein levels, as determined by immunoblotting (Fig 3c) . No change in the basal level of αSMA was observed in response to miR-145 over-expression in the absence of TGF-β1.
Overexpression of miR-143, a miRNA co-expressed with miR-145 as part of a bicistronic cluster (24) , resulted in a small decrease in the expression of αSMA transcript but had no effect on αSMA protein levels (Fig 3b&c) . In keeping with these findings, we observed a modest, but significant, reduction in the ability of fibroblasts to contract collagen gels in response to TGF-β1 compared to controls (Fig 3d) .
M a n u s c r i p t
Similar results with regards to αSMA expression were obtained using dermal fibroblasts, suggesting the effects of miR-145 are not tissue specific (Fig 3e,f) .
We next examined the ability of miR-145 to influence extracellular matrix production, alterations of which are associated with myofibroblastic CAF (19, 22, 23, 25) .
Heterologous over-expression of miR-145 was found to significantly and markedly decrease the expression of transcripts derived from a number of genes encoding components of the extracellular matrix, including FN1-EDA, connective tissue growth factor (CTGF), COL1A1, MMP2 and both variants of VCAN expressed in oral fibroblasts (VCAN V0 and V1), and to block the upregulation of these genes in response to TGF-β1 (Figure 4a-f ). The down-regulation of VCAN was also observed at the protein level, as determined by immunoblotting (Fig 4g) with the level of knockdown approaching that achieved by VCAN-specific siRNA (Fig 4g) . Overexpression of miR-143, previously reported to regulate VCAN expression (26) , had no effect on either VCAN transcript or protein levels (Fig 4g) . Over-expression of miR-145 attenuated the ability of myofibroblasts to stimulate cancer cell migration and invasion in a paracrine manner (Fig 4h&i) . Similar effects of miR-145 on the fibroblast phenotype were obtained with dermal fibroblasts (Fig 4j&k) .
miR-145 regulates the CAF phenotype
Having established the ability of miR-145 to inhibit the acquisition of a CAF-like myofibroblastic phenotype in normal oral fibroblasts, we next examined its effects in CAF. Over-expression of miR-145 in CAF resulted in a decrease in both basal and TGFβ-induced αSMA, COL1A1 and FN1-EDA transcript levels (Fig 5a-c) and a significant reduction in the ability of TGF-β1 to induce the formation of αSMA-rich stress fibres (Fig 5d) . As observed in normal fibroblasts, miR-145 overexpression Fig S2A-C) , and reduced both basal and TGF-β-induced VCAN protein expression (Fig 5e) . Over-expression of miR-145 in CAF inhibited paracrine stimulation of cancer cell migration in two of the four CAF cultures tested (Fig 5f) .
Each of the four CAF cultures used had a higher endogenous miR-145 expression relative to average NOF miR-145 levels (Table S1 ).
To further examine the regulation of CAF phenotype by miR-145 we investigated a possible correlation between miR-145 expression levels and, both endogenous and TGF-β-induced, αSMA gene expression. We found a significant, positive correlation between endogenous miR-145 and αSMA expression in both NOF and CAF cultures (R 2 =0.7387, p<0.001; Fig S3a) . However, it should be noted, if the fibroblast culture with the highest level of αSMA was omitted from the regression analysis, the correlation was no longer significant (R 2 =0.06846, p= 0.2278). There was also a trend towards a positive correlation (which didn't, however, reach significance) between CAF endogenous miR-145 levels and the magnitude of the TGF-β-induced αSMA ( Fig S3b) .
miR-145 rescues the CAF phenotype
In order to examine whether these findings would hold therapeutic potential we tested the ability of miR-145 to rescue the CAF phenotype. TGF-β1 treated NOF, which were subsequently transfected with miR-145 mimic, showed markedly reduced expression of CAF markers αSMA, COL1A1 and FN1-EDA (Fig 6a-d) and also a significant reduction in versican V0 and V1 expression (Fig 6e&f) . The same reversal of TGF-β1 induced CAF phenotype was seen in dermal fibroblasts (HDF ; Fig 6g-l) .
The extent of miR-145 overexpression was assessed by RT-qPCR in NOFs and
A c c e p t e d M a n u s c r i p t HDFs (Fig S4a&b) .
Discussion
The molecular mechanisms underlying the development of CAF from resident stromal fibroblasts are poorly understood, hampering the development of stromallydirected therapies. Here we identify miR-145 as a key regulator of the differentiation of myofibroblastic CAF from resting fibroblasts. We provide evidence that miR-145 levels are elevated in the majority of CAF isolated from oral squamous cell carcinomas compared to normal resting oral fibroblasts, and that induction of a myofibroblastic CAF-like phenotype in vitro results in induction of miR-145
expression. Furthermore, we show that miR-145 suppresses cytoskeletal and matricellular markers of myofibroblast activation, and paracrine stimulation of cancer cell migration and invasion, suggesting miR-145 up-regulation may serve to limit protumourigenic, myofibroblastic differentiation in the tumour microenvironment.
Whilst tumour-suppressive effects of miR-145 have been described in both tumour cells and fibroblasts (27) (28) (29) (30) , two recent studies suggested that miR-145 is restricted to, or at least significantly enriched in, cells of mesenchymal origin (9, 31) . In keeping with this, functions have been ascribed to miR-145 in a variety of mesenchymal cells, including smooth muscle cells and fibroblasts (32) (33) (34) (35) (36) . In both of these cell types miR-145 is most commonly described as having the ability to promote differentiation, although a very recent study demonstrated that the effects of miR-145 on the vascular smooth muscle cell (VSMC) phenotype are context-specific, and that miR-145 is able to inhibit responses to TGF-β1, limiting the differentiation of VSMCs (36) . This is consistent with our findings, in which we observe miR-145 levels to increase in response to TGF-β1 but to down-regulate numerous target genes induced by TGF- Myofibroblastic differentiation is a complex process regulated by both intrinsic and extrinsic cues. Among extrinsic cues, the ECM plays a prominent role, both through interaction of cells with individual components and by mechanical forces imposed by the ECM. In this study, we provide evidence that miR-145 reduces the synthesis of a variety of ECM components in the presence and absence of TGF-β1.
What is yet to be determined, however, is whether these are direct or indirect targets of miR-145.
Of those targets studied, only CTGF is reported to be directly targeted by miR-145 (42) ; we are currently seeking to validate this in primary fibroblasts. miR-145 has several documented targets in the TGF-β pathway including SMAD3 (43) and TGF-βRII (36), down-regulation of which may influence the production of ECM components. We propose that miR-145 regulates responses to TGF-β1 by targeting multiple components of the pathway, possibly differentially in response to yet undetermined additional context-specific cues. In the tumour microenvironment, this confers on miR-145 the ability to reduce the myofibroblastic, pro-tumourigenic CAF phenotype.
Here we have outlined a key role for mesenchymal miR-145 in a TGF-β1 feedback loop in stromal fibroblasts. Up-regulated by TGF-β1, miR-145 is able to dampen TGF-β1 mediated myofibroblast transdifferentiation and consequential protumourigenic effects in fibroblasts. This raises the possibility that miR-145 could be exogenously targeted to the tumour microenvironment to attenuate the protumourigenic myofibroblastic phenotype of CAF. It may also hold promise in other contexts in which myofibroblasts play a role, such as fibrotic disorders. miRNAmediated therapies are currently in clinical trials (reviewed in (44) ) and recent developments in miRNA delivery techniques have realised the possibility of Conditioned medium collected from cells exposed to TGF-β1 for 48 h was used in a transwell assay to assess the migration (g) or invasion through Matrigel (h) of H357 cancer cells. ****p<0.0001, ***p<0.001, **p<0.01 assessed using a paired, two tailed student's t-test. n=3, biological replicates in fibroblast strain indicated above. Proliferating NOF (NOF1) were transfected with 50 nM synthetic premiR-143, premiR-145 or a control, non-targeting premiR (negative premiR), incubated for 24 h before being exposed to TGF-β1 (5 ng/mL) or serum free DMEM control for a further 48 h. RNA was extracted and resulting cDNA subjected to qPCR for mature miR-145 (a) or αSMA (b). Total cellular lysate protein from cells transfected as described was immunoblotted for αSMA (c); additionally transfected cells (NOF2-4; data combined) were seeded into collagen I gels and their ability to contract the gels in following treatment with TGF-β1 (5 ng/mL) or vehicle control for 48 h determined (d). Human dermal primary fibroblasts (HDF) were transfected with miR-145 and treated with M a n u s c r i p t TGF-β1, as above. αSMA transcript levels were assessed by qPCR (e) and protein by immunoblotting (f) ****p<0.0001, ***p<0.001, **p<0.01 using a paired, two tailed student's t-test. All n=3, biological replicates in fibroblast strain indicated above.
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